Ximbio has completed an agreement with the American Type Culture Collection (ATCC) that will enable it to offer cells derived from ATCC parental lines for licence and academic distribution.
Many researchers employ widely adopted cell lines such as MCF7, HT 1080, U2OS to generate their own derivative/daughter cells because these parental lines are well characterised, accessible and above all immortal. The revenue share agreement will enable Ximbio to make 28 daughter cell lines available in the first instance. It marks an important step as Ximbio looks to manage an increasing number of cell lines from third party institutes.